Celleron Therapeutics announces encouraging clinical results with its new cancer drug CXD101 in heavily pre-treated unresponsive cancer patients

with No Comments

Download as a PDFOxford, UK, 1st December 2015; Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced that significant clinical activity was observed in the first human trial of its pioneering personalised cancer treatment CXD101 … Read More